Idarucizumab (Praxbind ® ) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients.

Autor:	Kalmanovich E; Department of Cardiology, Montpellier University Hospital, Montpellier Cedex 5, 34295, France., Battistella P; Department of Cardiology, Montpellier University Hospital, Montpellier Cedex 5, 34295, France., Rouviere P; Department of Cardiovascular Surgery, Montpellier University Hospital, France., Albat B; Department of Cardiovascular Surgery, Montpellier University Hospital, France., Frapier JM; Department of Cardiovascular Surgery, Montpellier University Hospital, France., Demaria R; Department of Cardiovascular Surgery, Montpellier University Hospital, France., Huet F; Department of Cardiology, Montpellier University Hospital, Montpellier Cedex 5, 34295, France., Agullo A; Department of Cardiology, Montpellier University Hospital, Montpellier Cedex 5, 34295, France.; Department of Cardiovascular Surgery, Montpellier University Hospital, France., Mourad M; Department of Anesthesiology & Critical Care Medicine, Arnaud de Villeneuve Hospital, Montpellier, France., Colson P; Department of Anesthesiology & Critical Care Medicine, Arnaud de Villeneuve Hospital, Montpellier, France., Leclercq F; Department of Cardiology, Montpellier University Hospital, Montpellier Cedex 5, 34295, France., Gaudard P; Department of Anesthesiology & Critical Care Medicine, Arnaud de Villeneuve Hospital, Montpellier, France., Roubille F; Department of Cardiology, Montpellier University Hospital, Montpellier Cedex 5, 34295, France.; PhyMedExp, Université de Montpellier, INSERM, CNRS, Cardiology Department, CHU de Montpellier, France.
Jazyk:	angličtina
Zdroj:	Future science OA [Future Sci OA] 2021 Feb 15; Vol. 7 (4), pp. FSO689. Date of Electronic Publication: 2021 Feb 15.
DOI:	10.2144/fsoa-2020-0186
Abstrakt:	Background: Novel oral anticoagulants are used in atrial fibrillation. Idarucizumab has been approved for reversal of dabigatran in situations of life-threatening hemorrhage or emergency surgery. Objectives: We report a single center experience of ten patients on dabigatran therapy who were given idarucizumab prior to heart transplantation. Methods & Results: The mean plasma concentration of dabigatran prior to reversal was 139 ± 89 ng/ml. Hemoglobin, hematocrit and platelet levels were decreased after surgery. Surgical procedures were successfully performed with no increased risk, especially regarding bleeding complications. All patients were alive after 90 days. Conclusion: Dabigatran reversal with idarucizumab in contexts of emergency surgery/urgent procedures is an attractive and safe option to be taken into consideration for patients with end stage heart disease awaiting transplantation and indication of anticoagulant therapy. Competing Interests: Financial & competing interests disclosure F Roubille and F Leclercq declare to have received honoraria for lectures from Boehringer-Ingelheim. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing support was provided by B Herve and was funded by Boehringer-Ingelheim. (© 2021 Francois Roubille.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu